» Articles » PMID: 34572598

The Effect of a Synthetic Estrogen, Ethinylestradiol, on the HERG Block by E-4031

Overview
Journal Biomolecules
Publisher MDPI
Date 2021 Sep 28
PMID 34572598
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of K-conductance through the human ether-a-go-go related gene (hERG) channel leads to QT prolongation and is associated with cardiac arrhythmias. We previously reported that physiological concentrations of some estrogens partially suppress the hERG channel currents by interacting with the S6 residue F656 and increase the sensitivity of hERG blockade by E-4031. Although these studies suggested that clinically used synthetic estrogens with similar structures have the marked potential to alter hERG functions, the hERG interactions with synthetic estrogens have not been assessed. We therefore examined whether ethinylestradiol (EE2), a synthetic estrogen used in oral contraceptives, affects hERG function and blockade by drugs. Supratherapeutic concentrations of EE2 did not alter amplitudes or kinetics of the hERG currents elicited by train pulses at 20 mV (0.1 Hz). On the other hand, EE2 at therapeutic concentrations reduced the degree of hERG current suppression by E-4031. The administration of EE2 followed by E-4031 blockade reversed the current suppression, suggesting that the interaction of EE2 and E-4031 alters hERG at the drug-binding site. The effects of EE2 on hERG blockade raised the possibility that other estrogens, including synthetic estrogens, can alter hERG blockade by drugs that cause QT prolongation and ventricular arrhythmias.

Citing Articles

Population-specific variations in predispose patients to delayed ventricular repolarization upon dihydroartemisinin-piperaquine therapy.

Camara M, Zhou Y, Dara A, Tekete M, Nobrega de Sousa T, Sissoko S Antimicrob Agents Chemother. 2024; 68(5):e0139023.

PMID: 38546223 PMC: 11064487. DOI: 10.1128/aac.01390-23.


Molecular Pathogenesis of Cardiac Arrhythmia.

Okamoto Y, Ono K Biomolecules. 2022; 12(10).

PMID: 36291601 PMC: 9599332. DOI: 10.3390/biom12101393.

References
1.
Napolitano C, Schwartz P, Brown A, Ronchetti E, Bianchi L, Pinnavaia A . Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 2000; 11(6):691-6. DOI: 10.1111/j.1540-8167.2000.tb00033.x. View

2.
Yu H, Zou B, Wang X, Li M . Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay. Acta Pharmacol Sin. 2016; 37(1):111-23. PMC: 4722980. DOI: 10.1038/aps.2015.143. View

3.
Kadish A, Greenland P, Limacher M, Frishman W, Daugherty S, Schwartz J . Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol. 2004; 9(4):366-74. PMC: 6932472. DOI: 10.1111/j.1542-474X.2004.94580.x. View

4.
Yang P, Perissinotti L, Lopez-Redondo F, Wang Y, DeMarco K, Jeng M . A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias. J Physiol. 2017; 595(14):4695-4723. PMC: 5509858. DOI: 10.1113/JP273142. View

5.
Ishii K, Nagai M, Takahashi M, Endoh M . Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. Cardiovasc Res. 2003; 57(3):651-9. DOI: 10.1016/s0008-6363(02)00774-5. View